Clinical trials
Phase 3 trials in Costa Rica
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
130 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 3 |
| 2002 | 4 |
| 2003 | 8 |
| 2004 | 3 |
| 2005 | 14 |
| 2006 | 10 |
| 2007 | 10 |
| 2008 | 13 |
| 2009 | 11 |
| 2010 | 3 |
| 2011 | 2 |
| 2013 | 2 |
| 2014 | 1 |
| 2015 | 4 |
| 2016 | 5 |
| 2017 | 3 |
| 2018 | 10 |
| 2019 | 7 |
| 2020 | 3 |
| 2021 | 3 |
| 2022 | 2 |
| 2023 | 4 |
| 2024 | 3 |
| 2025 | 1 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 98 |
| Terminated | 16 |
| Active, not recruiting | 9 |
| Recruiting | 6 |
| Suspended | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hoffmann-La Roche | 30 |
| Pfizer | 15 |
| Merck Sharp & Dohme LLC | 13 |
| AstraZeneca | 9 |
| GlaxoSmithKline | 9 |
| Sanofi | 8 |
| Novartis | 5 |
| Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 5 |
| Sanofi Pasteur, a Sanofi Company | 4 |
| Bristol-Myers Squibb | 3 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Breast Neoplasms | 9 |
| Carcinoma, Non-Small-Cell Lung | 8 |
| Arthritis, Rheumatoid | 7 |
| Asthma | 7 |
| Diabetes Mellitus, Type 2 | 7 |
| HIV Infections | 5 |
| Influenza, Human | 5 |
| Neoplasms | 4 |
| Schizophrenia | 4 |
| Tetanus | 4 |
Trials
Showing 76 to 100 of 130. Each trial links to its page on Pharma Observatory.
30 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.